Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Financial Statements and Exhibits

0

Interpace Diagnostics Group (NASDAQ:IDXG) Files An 8-K Financial Statements and Exhibits

Item 9.01 of the Original 8-K to (i) add the Amended and Restated
Security and Pledge Agreement, the Amended and Restated
Intellectual Property Security Agreement and the Amended and
Restated Guaranty, which are being filed as Exhibit 10.2, Exhibit
10.3 and Exhibit 10.4, respectively, to this Form 8-K/A and (ii)
refile in its entirety the Form of Common Stock Purchase Warrant
previously filed as Exhibit 4.3 to the Original 8-K, which is
being filed as Exhibit 4.3 to this Form 8-K/A. Other than as set
forth in this Explanatory Note, this Form 8-K/A does not amend
any other items in the Original 8-K or include any other
modifications to the exhibits included as part of the Original
8-K.

Item 9.01.Financial Statements and Exhibits

(d)Exhibits

Exhibit Number

Description

4.1

Senior Secured Note, dated March 23, 2017, by Interpace
Diagnostics Group, Inc. in favor of Hudson Bay Master Fund
Ltd.

4.2

Senior Secured Convertible Note, dated March 23, 2017, by
Interpace Diagnostics Group, Inc. in favor of Hudson Bay
Master Fund Ltd.

4.3*

Form of Common Stock Purchase Warrant

10.1

Exchange Agreement, dated as of March 22, 2017, by and
between Interpace Diagnostics Group, Inc. and Hudson Bay
Master Fund Ltd.

10.2*

Amended and Restated Security and Pledge Agreement, dated
as of March 23, 2017, by and among Interpace Diagnostics
Group, Inc., Interpace Diagnostics, LLC and Interpace
Diagnostics Corporation and Hudson Bay Master Fund Ltd.

10.3*

Amended and Restated Intellectual Property Security
Agreement, dated as of March 23, 2017, by and among
Interpace Diagnostics Group, Inc., Interpace Diagnostics,
LLC and Interpace Diagnostics Corporation and Hudson Bay
Master Fund Ltd.

10.4*

Amended and Restated Guaranty, dated as of March 23, 2017,
by Interpace Diagnostics, LLC and Interpace Diagnostics
Corporation in favor of Hudson Bay Master Fund Ltd.

10.5

Termination Agreement, dated as of March 22, 2017, by and
among Interpace Diagnostics Group, Inc., Interpace
Diagnostics, LLC, Interpace Diagnostics Corporation, PDI
Biopharma, LLC, Group DCA, LLC, Interpace Diagnostics Lab,
Inc. and RedPath Equityholder Representative, LLC

99.1

Press Release dated March 23, 2017

* Filed herewith

Previously filed


About Interpace Diagnostics Group (NASDAQ:IDXG)

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.

Interpace Diagnostics Group (NASDAQ:IDXG) Recent Trading Information

Interpace Diagnostics Group (NASDAQ:IDXG) closed its last trading session down -0.03 at 2.34 with 385,960 shares trading hands.